Frontlight ResearchEarly access
Taking peoplePhase 3
Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza
Key facts
- Who runs it
- Joincare Pharmaceutical Group Industry Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 177 people, planned
- Started
- 7 Nov 2025
- Planned end
- 15 Apr 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- JKN2301 Dry Suspension
- Oseltamivir Placebo
- Oseltamivir
- JKN2301 Placebo
- Record updated
- 21 January 2026
Who can take part
- Age
- 2 years to 11 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Pediatric patients within the specified age range
- Clinical presentation consistent with influenza, confirmed by a positive local rapid test or central laboratory PCR test
- Presentation for treatment within the early symptomatic phase of influenza illness
- Presence of fever and at least one respiratory symptom
- Ability to swallow oral suspension
- Parent/guardian and patient (as age-appropriate) able to provide informed consent/assent
Who cannot take part
- Presence of a concurrent bacterial infection requiring systemic therapy
- History of hypersensitivity to any component of the investigational products
- Use of prohibited medications (including other anti-influenza antivirals) within a specified period prior to enrollment
- Clinical signs suggestive of severe or complicated influenza infection
- Significant immunocompromised, or severe/uncontrolled comorbid conditions
- Any condition that, in the opinion of the investigator, would jeopardize patient safety or compliance with the study protocol
- requiring inpatient management
- Recent participation in another interventional clinical trial
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 2 and 11 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this phase III study is to learn if JKN2301 Dry Suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.
The 2 groups in the trial
- JKN2301 + Oseltamivir PlaceboTreatment being tested
Treatment: JKN2301 Dry Suspension and Oseltamivir Placebo
- Oseltamivir + JKN2301 PlaceboExisting treatment, for comparison
Treatment: Oseltamivir and JKN2301 Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza
- Criteria questions
- Built from NCT07357051, who can take part
- Record updated
- 21 January 2026